|Respiratory and sleep disorders in mucopolysaccharidosis.|
|Jump to Full Text|
|PMID: 23151682 Owner: NLM Status: Publisher|
|MPS encompasses a group of rare lysosomal storage disorders that are associated with the accumulation of glycosaminoglycans (GAG) in organs and tissues. This accumulation can lead to the progressive development of a variety of clinical manifestations. Ear, nose, throat (ENT) and respiratory problems are very common in patients with MPS and are often among the first symptoms to appear. Typical features of MPS include upper and lower airway obstruction and restrictive pulmonary disease, which can lead to chronic rhinosinusitis or chronic ear infections, recurrent upper and lower respiratory tract infections, obstructive sleep apnoea, impaired exercise tolerance, and respiratory failure. This review provides a detailed overview of the ENT and respiratory manifestations that can occur in patients with MPS and discusses the issues related to their evaluation and management.|
|Kenneth I Berger; Simone C Fagondes; Roberto Giugliani; Karen A Hardy; Kuo Sheng Lee; Ciarán McArdle; Maurizio Scarpa; Martin J Tobin; Susan A Ward; David M Rapoport|
|Type: JOURNAL ARTICLE Date: 2012-11-15|
|Title: Journal of inherited metabolic disease Volume: - ISSN: 1573-2665 ISO Abbreviation: J. Inherit. Metab. Dis. Publication Date: 2012 Nov|
|Created Date: 2012-11-15 Completed Date: - Revised Date: -|
Medline Journal Info:
|Nlm Unique ID: 7910918 Medline TA: J Inherit Metab Dis Country: -|
|Languages: ENG Pagination: - Citation Subset: -|
|Department Medicine, Physiology and Neuroscience, André Cournand Pulmonary Physiology Laboratory, Bellevue Hospital, New York University School of Medicine, New York, NY, USA, Kenneth.Berger@nyumc.org.|
|APA/MLA Format Download EndNote Download BibTex|
Journal ID (nlm-ta): J Inherit Metab Dis
Journal ID (iso-abbrev): J. Inherit. Metab. Dis
Publisher: Springer Netherlands, Dordrecht
© The Author(s) 2012
Received Day: 31 Month: 8 Year: 2012
Revision Received Day: 12 Month: 10 Year: 2012
Accepted Day: 15 Month: 10 Year: 2012
Electronic publication date: Day: 15 Month: 11 Year: 2012
pmc-release publication date: Day: 15 Month: 11 Year: 2012
Print publication date: Month: 3 Year: 2013
Volume: 36 Issue: 2
First Page: 201 Last Page: 210
PubMed Id: 23151682
Publisher Id: 9555
|Respiratory and sleep disorders in mucopolysaccharidosis|
|Kenneth I. BergerAff1Aff11||
Address: +1-212-5623752 +1-917-8292018 Kenneth.Berger@nyumc.org
|Simone C. FagondesAff2|
|Karen A. HardyAff4|
|Kuo Sheng LeeAff5|
|Martin J. TobinAff8|
|Susan A. WardAff9|
|David M. RapoportAff10|
Department Medicine, Physiology and Neuroscience, André Cournand Pulmonary Physiology Laboratory, Bellevue Hospital, New York University School of Medicine, New York, NY USA
Department Pulmonary Medicine, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
Department Genetics/UFRGS, Medical Genetics Service/HCPA and INAGEMP, Porto Alegre, Brazil
Children’s Hospital & Research Center Oakland, Oakland, CA USA
Mackay Memorial Hospital, Taipei, Taiwan
Birmingham Childrens Hospital, Birmingham, UK
Department Pediatrics, University of Padua, Padua, Italy
Hines VA Hospital, Hines, IL USA
Human Bio-Energetics Research Centre, Crickhowell, UK
Department of Medicine, New York University School of Medicine, New York, NY USA
Department of Medicine, Physiology and Neuroscience, New York University School of Medicine, 550 First Ave, Room RR108, New York, NY 10016 USA
|Communicated by footnote: Communicated by: Ed Wraith
The mucopolysaccharidoses (MPS) are rare inherited metabolic diseases associated with deficiencies in enzymes involved in the degradation of glycosaminoglycans (GAG) (Muenzer 2011). Progressive accumulation of GAG in multiple tissues and organs (Table 1) lead to an array of manifestations that worsen with age, ultimately resulting in severe morbidity and premature death (Muenzer 2011). Most patients share a typical appearance characterized by coarsened facial features, reduced height, and skeletal abnormalities. Other manifestations include impaired vision and hearing, hepatosplenomegaly, cardiovascular disease, spinal cord compression, and ear-nose-throat (ENT) and respiratory problems. Cognitive impairment is the main feature in MPS III and may occur in MPS I, II and VII. Although many similarities exist, the spectrum and severity of disease manifestations vary between and within the different MPS types.
This review addresses ENT and respiratory disorders occurring in MPS, and discusses their evaluation and management.
Respiration results from the interaction of pathways under cerebral control. The brain controls the synchronous movement of the diaphragm, ribs and abdomen; modulating influences are exerted by feedback from arterial blood gas tensions, pH and pulmonary-mechanical factors. The brain also controls phasic coordination of upper airway (UA) muscles, which interact with anatomic factors to determine the UA resistance. Coordinated activity of the chest wall and UA muscles is required to achieve normal ventilation. Changes in UA and diaphragmatic control occur with sleep onset, and can thus disrupt ventilation.
Respiratory disorders occur in all MPS types (John et al 2011; Leighton et al 2001; Lin et al 2010; Muhlebach et al 2011; Nashed et al 2009; Santamaria et al 2007; Semenza and Pyeritz 1988) (Table 2). However, due to low patient numbers no conclusions can be made regarding the prevalence and severity of these problems in each MPS type. The ENT and respiratory disorders can be divided into airway abnormalities, alterations in respiratory mechanics, and effects of sleep (Fig. 1 and Table 3).
Supraglottic manifestations are common in MPS and develop due to cranial and spinal abnormalities (e.g., flattened nasal bridge, short neck, high epiglottis, mandibular abnormalities, abnormal cervical vertebrae) and GAG deposition in the mouth, nose and throat (Leboulanger et al 2011; Leighton et al 2001; Myer 1991; Shih et al 2002). Oral manifestations include gingival hyperplasia, mucosal oedema, mucoid secretions, and impaired opening of the mouth. Chronic rhinosinusitis and chronic otitis media may occur and produce hearing impairment (John et al 2011; Muhlebach et al 2011), and the rhinosinusitis can contribute to UA obstruction during sleep.
GAG storage can also cause distension of the tongue, adenoids and/or tonsils with formation of collapsible, space-occupying lesions in pharyngolaryngeal walls (Simmons et al 2005). In extreme cases, excessive tissue at the arytenoid cartilages and aryepiglottic folds can prolapse into the laryngeal inlet causing stridor and airway compromise (Simmons et al 2005). Obstruction is often worsened by presence of thickened secretions throughout the upper and lower respiratory tracts (Leighton et al 2001). ENT manifestations are among the first disease-specific manifestations to appear, may trigger diagnosis of MPS (Muhlebach et al 2011; Wold et al 2010), and tend to progress with age.
Airway abnormalities and airway collapse may also occur in infraglottic airways, including the trachea and central airways. Tracheobronchomalacia may develop secondary to GAG deposition in the tracheobronchial cartilage (Nagano et al 2007; Pelley et al 2007; Shih et al 2002; Sims and Kempiners 2007). Alternatively, tracheal collapse can occur due to decreased tracheal traction from decreased lung volume (Heinzer et al 2005), although this has not been specifically shown in MPS. MPS IV patients may develop airway occlusion upon neck flexion. These patients assume a “sniff position” (extension of the neck to increase airway patency) during wakefulness and may sleep in the prone position. Clinical manifestations include dyspnoea, difficulty clearing secretions, cough, wheezing, and recurrent bronchitis or pneumonia (John et al 2011; Leighton et al 2001; Muhlebach et al 2011; Murgu and Colt 2006; Pelley et al 2007). Another study also suggested alveolar and interstitial pulmonary involvement by GAG deposition (Semenza and Pyeritz 1988). Airway obstruction and parenchymal abnormality have potential to impair pulmonary O2 uptake and CO2 excretion.
Multiple abnormalities in MPS patients can reduce ventilatory capacity, manifesting as reduction in vital capacity (VC). Kyphoscoliosis and pectus carinatum are common and alter chest wall shape and structure. Diaphragm excursion may be compromised by liver and spleen enlargement (Buhain et al 1975; Giugliani et al 2007; Leighton et al 2001). Diaphragmatic weakness may result from spinal cord compression above the phrenic nerve origin (C3-C5), but there is currently no evidence for this hypothesis.
Pulmonary function can also be affected by the characteristic short stature and skeletal dysplasia. In MPS disorders associated with short stature (e.g., MPS VI), patient height is the primary determinant of VC and improved pulmonary function during enzyme replacement therapy (ERT) is frequently associated with growth and increased stature (Swiedler et al 2005; Harmatz et al 2010).
The combined effect of these alterations in respiratory mechanics coupled with airway abnormalities may lead to respiratory failure.
Ventilatory compromise is exacerbated by normal sleep mechanisms that increase UA collapsibility, thus magnifying any impairment to generation of inspiratory effort. The effects of sleep are particularly evident during REM sleep, which causes loss of tone in accessory muscles of respiration and reduction in ventilatory CO2 chemosensitivity (Dempsey et al 2010). Due to the changes that occur with sleep onset, ventilatory compromise often first manifests as sleep disordered breathing (SDB) and unexplained hypoxemia during sleep.
SDB occurs in >80 % of MPS patients (John et al 2011; Leighton et al 2001; Semenza and Pyeritz 1988). It can be categorized as either obstructive sleep apnoea (OSA) or sustained hypoventilation. OSA occurs from an interaction between abnormalities of the skull and GAG deposition in the UA and perhaps from remote effects of thoracic deformation causing reduced lung volumes. OSA can lead to daytime sleepiness and long-term cardiovascular sequellae and often presents as loud and disruptive snoring. Sleep studies demonstrate recurrent short episodes (<90 s) of either reduced or absent ventilation due to UA obstruction. In more advanced stages, compensation for CO2 retention during individual SDB events may be impaired by reduction of VC and inability to increase ventilation during inter-event intervals (Fig. 2) (Berger et al 2000). These patients exhibit progressive CO2 retention throughout the night, i.e., nocturnal hypoventilation (Mellies et al 2003; Ragette et al 2002).
A restrictive abnormality and/or diaphragmatic weakness may also cause sustained periods of hypoventilation. Sleep studies demonstrate prolonged periods (several minutes) of arterial O2 desaturation consequent to hypoventilation (Leighton et al 2001). Reduced VC, which is influenced by respiratory muscle strength, may be a good predictor of SDB severity (Ragette et al 2002). Whereas patients with VC <60 % of predicted have a predisposition to SDB, those with a VC <40 % of predicted are prone to sustained hypoventilation and CO2 retention.
If improperly managed, nocturnal hypoventilation may lead to pulmonary hypertension, cor pulmonale and eventually respiratory failure (John et al 2011; Semenza and Pyeritz 1988), a common cause of death in MPS (Leighton et al 2001).
Tracheal distortion is characteristic for MPS and may reflect disproportionate length of the trachea relative to the shortened spinal length (Walker et al 2003). In combination with laxity of tracheal tissue, it can cause airway collapse (Walker et al 2003). Cervical or lumbar spinal cord lesions may weaken expiratory muscles, impair cough and reduce secretion clearance, predisposing patients to recurrent pneumonia. In patients with cardiac abnormalities or chronic respiratory failure, nocturnal shift in leg fluid volume may cause UA oedema. Furthermore, the respiratory arousal threshold (i.e., the ease with which an individual wakes up in response to respiratory stimuli) may be modified due to brain modifications. However, these issues remain to be investigated.
Classification systems for grading mouth and UA abnormalities in MPS include a modified Mallampati classification system based on visibility of the tonsils, pillars, uvula and soft palate and a classification system for grading tonsillar hypertrophy (Friedman et al 1999). Computed tomography (CT) of retropalatal and retroglossal spaces can demonstrate reduction in UA volume in MPS patients (Santamaria et al 2007). Multi-detector CT imaging can also evaluate airway size, airway structure and the lung parenchyma (Ingelmo et al 2011) (Fig. 3i and j).
Dynamic changes in the airway during respiration can be evaluated using flexible endoscopy (Fig. 3a, b, c, d, e, f, g and h). Fiberoptic examination is preferably done in a sitting position, which requires less ventilatory support than the supine position. Pharyngeal and laryngeal abnormalities can be classified based on the level of mucosal alteration (personal communication Dr. A. Keilmann). Grading systems based on adenoid hypertrophy and obstruction of the choanal opening and tubal ostium exist to evaluate nasal cavity obstruction (Cassano et al 2003; Josephson et al 2011; Parikh et al 2006).
Plain roentgenograms of the chest, spine and soft tissue of the neck may demonstrate airway obstruction, atelectasis, skeletal changes that cause restrictive disease and/or spinal cord compression (Fig. 3k and l). Magnetic resonance imaging may provide information on skeletal changes, but has limited utility for evaluating lung parenchyma. Imaging MPS patients can be challenging. Sedation may be required for young or uncooperative patients, although complications may occur due to the high anaesthetic risk (Walker et al 2012).
Respiratory symptoms and hypoventilation may not be detected as many patients are inactive and since respiratory dysfunction is often poorly correlated with clinical appearance. Nevertheless, anticipation of respiratory problems and management at an early stage is important to maximize treatment outcome. Symptoms that require evaluation include progressive dyspnoea, reduced physical activity, exercise intolerance, wheezing or stridor, tachycardia and cyanosis.
Spirometry is the most frequent test utilized in MPS to assess the VC and the forced expiratory volume in 1 s (FEV1). Reduction in VC is suggestive of a restrictive abnormality while reduction in FEV1 (expressed as FEV1/VC) indicates airflow obstruction. Reduction in VC can reflect changes in lung compliance, chest wall compliance, and/or neuromuscular weakness. Reduced VC may also result from air trapping. Standard normal values for spirometry cannot be applied in MPS patients due to the disease-induced growth impairment and expressing VC as a % of normal is of limited value (Swiedler et al 2005). In addition, spirometry may not be possible in children who are too young to cooperate (< 5 years) and in patients with cognitive impairment. Despite its limitations, spirometry remains a valid clinical tool since all respiratory abnormalities that occur in MPS produce a decrease in VC. Spirometry has been commonly used for screening, to determine longitudinal disease progression and assess response to therapy.
Maximum voluntary ventilation (MVV) can be assessed as an alternative to spirometry. However, this test is physically demanding and can be difficult for MPS patients. Promising alternatives to assess for airflow obstruction include multiple breath inert gas washout and impulse oscillometry. These tests are performed during tidal breathing and may detect early airway disease (Aurora et al 2005; Oppenheimer et al 2007; Pasker et al 1996; Klug and Bisgaard 1996; Hellinckx et al 1998).
The degree of pulmonary restriction or hyperinflation can be measured using plethysmograhy, helium dilution or nitrogen washout. The diagnosis and management of parenchymal disease requires measurement of diffusion. This measurement is only reliable if the minimum volume inspired is 1.2 L and may not be possible in MPS patients with reduced lung capacity.
Respiratory failure occurs from an imbalance between ventilation and metabolic rate. It can be identified by presence of hypercapnia on analysis of arterial blood gases. Since arterial blood gas analysis may not be available in the outpatient clinic, serum bicarbonate (HCO3-) concentration serves as a screening test since elevated values may indicate renal compensation for respiratory acidosis. If the serum [HCO3-] is ≥28 mEq/L, respiratory failure should be suspected and assessment of arterial blood gases should be considered (Mokhlesi et al 2007).
Sleep studies/polysomnograpy are used to diagnose and determine severity of respiratory sleep disorders. Since the incidence of SDB is high in MPS, polysomnography should be performed in all patients after diagnosis. Studies can be repeated based on presence of snoring, excessive daytime somnolence, development of respiratory failure and reduction in VC. Typical findings include recurrent OSA, tachycardia, decrease in arterial O2 saturation and recurrent arousal (Kamin 2008). It is important to distinguish OSA from sustained hypoventilation as these require different treatment approaches. Sustained nocturnal hypoventilation is suggested by oxygen desaturation in absence of OSA and can be confirmed by an increase in PCO2 during sleep, but this often carries over into wakefulness.
Exercise intolerance in MPS patients is generally measured using timed stair climbing or walk tests (e.g., 6- and 12-min walk tests [MWT]) (Harmatz et al 2008; Muenzer et al 2006; Wraith et al 2004). The 6-MWT is a practical test of submaximal functional capacity which mimics daily activities (e.g., American Thoracic Society 2002). Timed walk tests are used to assess functional status, monitor disease progression and response to interventions. The distance walked is generally the only variable that is evaluated. Valuable additional information could be obtained by measuring resting and end-exercise heart rate and arterial O2 saturation (e.g., American Thoracic Society 2002). Reference values for the 6-MWT exist (Enright and Sherrill 1998; Li et al 2007); however, applicability in MPS is unclear due to the associated cognitive and physical impediment.
Although not currently used, cardiopulmonary exercise testing might be valuable because of its wider diagnostic scope in terms of respiratory, cardio-circulatory and muscle-metabolic function (American Thoracic Society/American College of Chest Physicians 2003; Wasserman et al 2012). The symptom-limited ramp test provides a gradational stress spanning the entire tolerance range, with breath-by-breath measurement of ventilatory, gas-exchange and cardiovascular variables providing the substrate for analysing the causes of exercise intolerance, based on profiles of physiological system function.
UA collapse at the pharyngeal and laryngeal level may occur due to rhinitis or adenoidal obstruction. Treatments may include nasal decongestions to control excessive mucus production, and steroids to reduce swelling. Adenoidectomy and/or tonsillectomy are also often required, and frequently performed before diagnosis of MPS. The procedure can be dangerous as surgeons may not anticipate potential anaesthetic and surgical complications and procedures should be performed by experienced personnel (Walker et al 2012; Simmons et al 2005). The operative field is frequently limited by thick and hard oropharyngeal tissue and UA scar tissue that may compromise the already small airway (Yeung et al 2009). In advanced cases, andenotonsillectomy can be inadequate or impossible. Moreover, any improvements achieved may be temporary because of progressive involvement of the oropharynx and trachea (Kamin 2008; Muhlebach et al 2011).
Patients with lower airway obstruction may use inhaled steroids to decrease airway inflammation. Because of instability of the tracheal and bronchial wall, patients may respond better to an anticholinergic bronchodilator agent than to a beta-agonist (Muhlebach et al 2011).
The presence of SDB should prompt evaluation of the UA. Removal of tonsils and adenoids, if enlarged, may alleviate UA obstruction. SDB can also be managed by application of continuous positive airways pressure (CPAP), which delivers air at an elevated pressure using a mask that fits around the nose +/− mouth (Sullivan et al 1981; Rapoport et al 1982; Ginzburg et al 1990). The pressure acts as a dynamic stent and prevents airway collapse during inspiration. Nocturnal hypoventilation should be suspected if arterial O2 desaturation persists with CPAP or occurs in the absence of OSA (Berger et al 2001). In this case, non-invasive ventilator support systems (e.g., bilevel positive airway pressure) can be utilized and a backup respiratory rate can be added to prevent sustained hypoventilation. (Muhlebach et al 2011). Assisted ventilation may provide respiratory muscle rest and improve sleep quality, relieve nocturnal dyspnoea and lead to normalization of daytime blood gases. Supplemental O2 can be added if arterial O2 desaturation persists but should be used with caution as it may suppress ventilatory and arousal drives. Careful titration of the rate of O2 administration and monitoring of arterial CO2 levels are required to prevent O2-induced hypercapnia.
As compliance with CPAP and non-invasive ventilation is often low in MPS, compliance monitoring is imperative. In addition, leaks due to poor-fitting masks reduce treatment efficacy (Kamin 2008; Muhlebach et al 2011). Patients who adopt a sniff position may require specialized attention to ensure comfortable and adequate therapy. If properly used, CPAP and bilevel devices will improve breathing during sleep and provide relief of daytime somnolence and other consequences of SDB.
Tracheostomy may be required either when CPAP or non-invasive ventilation is ineffective or tracheomalacia and UA obstruction are present during wakefulness (Muhlebach et al 2011; Wold et al 2010). However, placement of the tracheostomy tube can be difficult and may be associated with stomal narrowing, granulation formation, infrastomal tracheal stenosis, wound infection, and tracheomalacia (Jeong et al 2006; Muhlebach et al 2011; Pelley et al 2007; Sims and Kempiners 2007). Problems may persist due to persistent airway collapse distal to the tip of the endotracheal tube (Pelley et al 2007) and patient preference for sleeping in the prone position. When the above therapies are ineffective, uncontrolled respiratory failure with cor pulmonale may develop and death may occur.
Multiple supportive therapies are required to maintain optimal functional status. All patients should receive regular vaccinations, including pneumococcus and influenza vaccinations. Treatment of respiratory tract infections should be early and aggressive. Impairment in secretion clearance can be addressed by both manual and mechanical techniques. Inhaled bronchodilators can be used in conjunction with these airway clearance techniques. Bronchodilators and corticosteroids (inhaled and/or oral) may be useful if concurrent asthma is present. As restrictive pulmonary disease may be caused be spinal cord compression, pulmonary function may also improve after decompression surgery.
ERT is available for and beneficial in patients with MPS I, II, and VI. A positive impact has been demonstrated on 6- or 12-MWT and on pulmonary function (Clarke et al 2009; Harmatz et al 2004, 2005, 2006; Muenzer et al 2011, 2006; Okuyama et al 2010; Wraith et al 2004).
An open-label extension study of ERT in MPS VI showed sustained improvement in walking distance for up to 240 weeks (Harmatz et al 2008). In addition, FEV1 and VC increased (11 % and 17 %, respectively) after 96 weeks of ERT with continued improvement thereafter (Fig. 4) (Harmatz et al 2010). Sustained improvement in MVV has also been demonstrated. These findings suggest that improved exercise tolerance in this population was related, at least partly, to improved pulmonary function.
The impact of ERT on pulmonary function should be interpreted in relationship to patient age. In younger children, increases in pulmonary function over time may (partly) be explained by growth. In line with this consideration, improvement in VC was only seen in patients with MPS II up to 18 years old (Muenzer et al 2011). In contrast, in MPS VI patients, (Harmatz et al 2010) increases in VC and FEV1 were observed in patients >12 years old despite minimal increases in height. In these patients, improvement in pulmonary function could only be explained by mechanisms other than growth, such as changes in bony structure, improvements in mobility, joint contractures or respiratory muscle function, shrinking of liver and spleen, or decreased GAG deposition in soft tissues. In adolescent patients, changes in pulmonary function may also be related to puberty.
Although haematopoietic stem cell transplantation (HSCT) is beneficial, and superior to ERT, for prevention of cognitive decline in young patients with MPS IH, effects in other MPS types tend to be poor (Rovelli 2008). Its use has been limited in the past by a high morbidity and mortality rate and the lack of matched donors, but this is changing with the increasing use of cord blood allowing a shorter interval between diagnosis and HSCT and a lower graft failure rate (Turbeville et al 2011; Prasad and Kurtzberg 2010). Most knowledge on the effect of HSCT on pulmonary function is based on case reports, some suggesting a positive impact (Krivit et al 1984; Wang et al 2008).
The high prevalence of ENT and respiratory manifestations in MPS patients, their severity, and their appearance early in the disease course dictate that evaluation and follow-up of these problems is extremely important. Since asymptomatic patients may have severely impaired pulmonary function, pulmonary disease may go undetected for years without appropriate screening. However, the measurement of pulmonary function in MPS patients remains an important challenge due to the complexity of the disease and a lack of data on “usual pulmonary function” in these patients. Nevertheless, longitudinal follow-up of absolute values can be useful for monitoring the evolution of respiratory disease in a single patient. Current management guidelines for MPS I and MPS VI therefore recommend pulmonary function testing at diagnosis and every 6–12 months thereafter (Giugliani et al 2007; Muenzer et al 2009).
This review has addressed the pathophysiological mechanisms underlying respiratory manifestations in the different types of MPS. In addition, opportunities for enhanced evaluation of pulmonary function in these patients were highlighted. More sophisticated evaluation should help determine the mechanisms underlying the impact of ERT on exercise tolerance, VC, and FEV1.
Details of the contributions of individual authors
All authors have contributed to the content of the manuscript and revised it critically for important intellectual content.
The authors are grateful to Ismar Healthcare NV for their assistance in writing of the manuscript, which was funded by BioMarin Pharmaceutical Inc.
The preparation of this manuscript was supported by BioMarin Pharmaceutical Inc.
Kenneth Berger has received consultancy fees and/or speaker honoraria from BioMarin and Genzyme. Simone C. Fagondes received a fee for a conference at the respiratory function and anaesthesia meeting supported by BioMarin 2012. Roberto Giugliani has received investigator fees, and/or travel grants, and/or speaker honoraria and/or consultancy fees from Actelion, Amicus, BioMarin, Genzyme and Shire. Kuo Sheng Lee received travel grants and speaker honorarium from BioMarin for attending a MPS conference. Karen Ann Hardy and Ciarán McArdle received honorarium and expenses from BioMarin for attending MPS meetings sponsored by BioMarin. Maurizio Scarpa received unrestricted research and travel grants from BioMarin, Actelion, Genzyme and Shire. Martin J. Tobin has received royalties on a book, “Principles and Practice of Mechanical Ventilation”, published by McGraw-Hill, Inc, New York. Susan A. Ward has no conflicts of interest. David M. Rapoport has received consultancy fees and speaker honoraria from BioMarin and consultancy fees, speaker honoraria and patent royalties for nasal CPAP from Fisher & Paykel Healthcare.
This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
|American Thoracic SocietyATS statement: guidelines for the six-minute walk testAm J Respir Crit Care MedYear: 200216611111712091180|
|American Thoracic Society/American College of Chest PhysiciansStatement on cardiopulmonary exercise testingAm J Respir Crit Care MedYear: 2003167211–2772003|
|Aurora P,Bush A,Gustafsson P,et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosisAm J Respir Crit Care MedYear: 200517124925610.1164/rccm.200407-895OC15516530|
|Berger KI,Ayappa I,Sorkin IB,Norman RG,Rapoport DM,Goldring RM. CO2 homeostasis during periodic breathing in obstructive sleep apneaJ Appl PhysiolYear: 20008825726410642388|
|Berger KI,Ayappa I,Chatr-amontri B,Marfatia A,et al. Obesity hypoventilation syndrome as a spectrum of respiratory disturbances during sleepChestYear: 20011201231123810.1378/chest.120.4.123111591566|
|Buhain WJ,Rammohan G,Berger HW. Pulmonary function in Morquio’s disease: a study of two siblingsChestYear: 197568414510.1378/chest.68.1.41807454|
|Canani SE,John AB,Schwartz IV,et al. Manejo de apnéia do sono em um paciente com mucopolysaccharidoseHypn J Clin Exp Sleep ResYear: 200334041|
|Cassano P,Gelardi M,Cassano M,Fiorella ML,Fiorella R. Adenoid tissue rhinopharyngeal obstruction grading based on fiberendoscopic findings: a novel approach to therapeutic managementInt J Pediatr OtorhinolaryngolYear: 2003671303130910.1016/j.ijporl.2003.07.01814643473|
|Clarke LA,Wraith JE,Beck M,et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis IPediatricsYear: 200912322924010.1542/peds.2007-384719117887|
|Dempsey JA,Veasey SC,Morgan BJ,O’Donnell CP. Pathophysiology of sleep apneaPhysiol RevYear: 2010904711210.1152/physrev.00043.200820086074|
|Enright PL,Sherrill DL. Reference equations for the six-minute walk in healthy adultsAm J Respir Crit Care MedYear: 1998158138413879817683|
|Friedman M,Tanyeri H,La Rosa M,et al. Clinical predictors of obstructive sleep apneaLaryngoscopeYear: 19991091901190710.1097/00005537-199912000-0000210591345|
|Ginzburg AS,Önal E,Aronson RM,Schild JA,Mafee MF,Lopata M. Successful use of nasal-CPAP for obstructive sleep apnea in Hunter syndrome with diffuse airway involvementChestYear: 1990971496149810.1378/chest.97.6.14962112082|
|Giugliani R,Harmatz P,Wraith JE. Management guidelines for mucopolysaccharidosis VIPediatricsYear: 200712040541810.1542/peds.2006-218417671068|
|Harmatz P,Whitley CB,Waber L,et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)J PediatrYear: 200414457458010.1016/j.jpeds.2004.03.01815126989|
|Harmatz P,Ketteridge D,Giugliani R,et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatasePediatricsYear: 2005115e681e68910.1542/peds.2004-102315930196|
|Harmatz P,Giugliani R,Schwartz I,et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyJ PediatrYear: 200614853353910.1016/j.jpeds.2005.12.01416647419|
|Harmatz P,Giugliani R,Schwartz IVD,et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfataseMol Genet MetabYear: 20089446947510.1016/j.ymgme.2008.04.00118502162|
|Harmatz P,Yu ZF,Giugliani R,et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfataseJ Inherit Metab DisYear: 201033516010.1007/s10545-009-9007-820140523|
|Heinzer RC,Stanchina ML,Malhotra A,et al. Lung volume and continuous positive airway pressure requirements in obstructive sleep apneaAm J Respir Crit Care MedYear: 200517211411710.1164/rccm.200404-552OC15817803|
|Hellinckx J,De Boeck K,Bande-Knops J,van der Poel M,et al. Bronchodilator response in 3–6.5 years old healthy and stable asthmatic childrenEur Respir JYear: 19981243844310.1183/09031936.98.120204389727798|
|Ingelmo PM,Parini R,Grimaldi M,et al. Multidetector computed tomography (MDCT) for preoperative airway assessment in children with mucopolysaccharidosesMinerva AnestesiolYear: 20117777478021730924|
|Jeong HS,Cho DY,Ahn KM,Jin DK. Complications of tracheotomy in patients with mucopolysaccharidoses type II (Hunter syndrome)Int J Pediatr OtorhinolaryngolYear: 2006701765176910.1016/j.ijporl.2006.05.02116831472|
|John A,Fagondes S,Schwartz I,et al. Sleep abnormalities in untreated patients with mucopolysaccharidosis type VIAm J Med Genet AYear: 2011155A1546155121638759|
|Josephson GD,Duckworth L,Hossain J. Proposed definitive grading system tool for the assessment of adenoid hyperplasiaLaryngoscopeYear: 201112118719310.1002/lary.2121521120829|
|Kamin W. Diagnosis and management of respiratory involvement in Hunter syndromeActa Paediatr SupplYear: 200897576010.1111/j.1651-2227.2008.00650.x18339190|
|Klug B,Bisgaard H. Measurement of lung function in awake 2–4-year-old asthmatic children during methacholine challenge and acute asthma: a comparison of the impulse oscillation technique, the interrupter technique, and transcutaneous measurement of oxygen versus whole-body plethysmographyPediatr PulmonolYear: 19962129030010.1002/(SICI)1099-0496(199605)21:5<290::AID-PPUL4>3.0.CO;2-R8726154|
|Krivit W,Pierpont ME,Ayaz K,et al. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantationN Engl J MedYear: 19843111606161110.1056/NEJM1984122031125046150438|
|Leboulanger N,Louis B,Vialle R,Heron B,Fauroux B. Analysis of the upper airway by the acoustic reflection method in children with mucopolysaccharidosisPediatr PulmonolYear: 20114658759410.1002/ppul.2140921280243|
|Leighton SEJ,Papsin B,Vellodi A,Dinwiddie R,Lane R. Disordered breathing during sleep in patients with mucopolysaccharidosesInt J Pediatr OtorhinolaryngolYear: 20015812713810.1016/S0165-5876(01)00417-711278021|
|Li AM,Yin J,Au JT,et al. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 yearsAm J Respir Crit Care MedYear: 200717617418010.1164/rccm.200607-883OC17463419|
|Lin HY,Chen MR,Lin CC,et al. Polysomnographic characteristics in patients with mucopolysaccharidosesPediatr PulmonolYear: 2010451205121210.1002/ppul.2130920717914|
|Mellies U,Ragette R,Schwake C,Boehm H,Voit T,Teschler H. Daytime predictors of sleep disordered breathing in children and adolescents with neuromuscular disordersNeuromuscul DisordYear: 20031312312810.1016/S0960-8966(02)00219-512565909|
|Mokhlesi B,Tulaimat A,Faibussowitsch I,et al. Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apneaSleep BreathYear: 20071111712410.1007/s11325-006-0092-817187265|
|Muenzer J. Overview of the mucopolysaccharidosesRheumatol (Oxf)Year: 201150Suppl 5v4v1210.1093/rheumatology/ker394|
|Muenzer J,Wraith JE,Beck M,et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)Genet MedYear: 2006846547310.1097/01.gim.0000232477.37660.fb16912578|
|Muenzer J,Wraith JE,Clarke LA. Mucopolysaccharidosis I: management and treatment guidelinesPediatricsYear: 2009123192910.1542/peds.2008-041619117856|
|Muenzer J,Beck M,Eng CM,et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndromeGenet MedYear: 2011139510110.1097/GIM.0b013e3181fea45921150784|
|Muhlebach MS,Wooten W,Muenzer J. Respiratory manifestations in mucopolysaccharidosesPaediatr Respir RevYear: 20111213313810.1016/j.prrv.2010.10.00521458742|
|Murgu SD,Colt HG. Tracheobronchomalacia and excessive dynamic airway collapseRespirologyYear: 20061138840610.1111/j.1440-1843.2006.00862.x16771908|
|Myer CM III. Airway obstruction in Hurler’s syndrome–radiographic featuresInt J Pediatr OtorhinolaryngolYear: 199122919610.1016/0165-5876(91)90101-G1917344|
|Nagano R,Takizawa S,Hayama N,et al. Three-dimensional CT and histopathological findings of airway malacia in Hunter syndromeTokai J Exp Clin MedYear: 200732596121319059|
|Nashed A,Al-Saleh S,Gibbons J,et al. Sleep-related breathing in children with mucopolysaccharidosisJ Inherit Metab DisYear: 20093254455010.1007/s10545-009-1170-419562504|
|Okuyama T,Tanaka A,Suzuki Y,et al. Japan Elaprase® Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II)Mol Genet MetabYear: 201099182510.1016/j.ymgme.2009.08.00619773189|
|Oppenheimer BW,Goldring RM,Herberg ME,et al. Distal airway function in symptomatic subjects with normal spirometry following World Trade Center dust exposureChestYear: 20071321275128210.1378/chest.07-091317890470|
|Parikh SR,Coronel M,Lee JJ,Brown SM. Validation of a new grading system for endoscopic examination of adenoid hypertrophyOtolaryngol Head Neck SurgYear: 200613568468710.1016/j.otohns.2006.05.00317071294|
|Pasker HG,Schepers R,Clement J,et al. Total respiratory impedance measured by means of the forced oscillation technique in subjects with and without respiratory complaintsEur Respir JYear: 1996913113910.1183/09031936.96.090101328834346|
|Pelley CJ,Kwo J,Hess DR. Tracheomalacia in an adult with respiratory failure and Morquio syndromeRespir CareYear: 20075227828217328826|
|Prasad VK, Kurtzberg J (2010) Transplant outcomes in mucopolysaccharidoses. Semin Hematol 47: 59–69|
|Ragette R,Mellies U,Schwake C,Voit T,Teschler H. Patterns and predictors of sleep disordered breathing in primary myopathiesThoraxYear: 20025772472810.1136/thorax.57.8.72412149535|
|Rapoport DM,Sorkin B,Garay SM,Goldring RM. Reversal of “Pickwickian syndrome” by long-term use of nocturnal nasal-airway pressureNew Engl J MedYear: 198230793193310.1056/NEJM1982100730715076810179|
|Rovelli AM. The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an updateBone Marrow TransplantYear: 200841Suppl 2S87S8910.1038/bmt.2008.6218545253|
|Santamaria F,Andreucci MV,Parenti G,et al. Upper airway obstructive disease in mucopolysaccharidoses: polysomnography, computed tomography and nasal endoscopy findingsJ Inherit Metab DisYear: 20073074374910.1007/s10545-007-0555-517570075|
|Semenza GL,Pyeritz RE. Respiratory complications of mucopolysaccharide storage disordersMed (Baltim)Year: 198867209219|
|Shih SL,Lee YJ,Lin SP,Sheu CY,Blickman JG. Airway changes in children with mucopolysaccharidosesActa RadiolYear: 200243404310.1034/j.1600-0455.2002.430108.x11972460|
|Simmons MA,Bruce IA,Penney S,Wraith E,Rothera MP. Otorhinolaryngological manifestations of the mucopolysaccharidosesInt J Pediatr OtorhinolaryngolYear: 20056958959510.1016/j.ijporl.2005.01.01715850680|
|Sims HS,Kempiners JJ. Special airway concerns in patients with mucopolysaccharidosesRespir MedYear: 20071011779178210.1016/j.rmed.2007.02.01317412578|
|Sullivan CE,Issa FG,Berthon-Jones M,Eves L. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the naresLancetYear: 1981186286510.1016/S0140-6736(81)92140-16112294|
|Swiedler SJ,Beck M,Bajbouj M,et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)Am J Med GenetYear: 2005134A14415010.1002/ajmg.a.3057915690405|
|Turbeville S,Nicely H,Rizzo JD,et al. Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VIMol Genet MetabYear: 201110211111510.1016/j.ymgme.2010.09.01020980181|
|Walker PP,Rose E,Williams JG. Upper airways abnormalities and tracheal problems in Morquio’s diseaseThoraxYear: 20035845845910.1136/thorax.58.5.45812728175|
|Walker R, Belani KG, Braunlin EA et al (2012) Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis. doi:10.1007/s10545-012-9563-1|
|Wang CC,Hwu WL,Lin KH. Long-term follow-up of a girl with Maroteaux-Lamy syndrome after bone marrow transplantationWorld J PediatrYear: 2008415215410.1007/s12519-008-0031-918661775|
|Wasserman K,Hansen JE,Sue DY,Stringer WW,Sietsema KE,Sun X-G,Whipp BJ. Principles of exercise testing and interpretationYear: 20125PhiladelphiaLippincott Williams & Wilkins|
|Wold SM,Derkay CS,Darrow DH,Proud V. Role of the pediatric otolaryngologist in diagnosis and management of children with mucopolysaccharidosesInt J Pediatr OtorhinolaryngolYear: 201074273110.1016/j.ijporl.2009.09.04219931921|
|Wraith JE,Clarke LA,Beck M,et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human a-L-iduronidase (laronidase)J PediatrYear: 200414458158810.1016/j.jpeds.2004.01.04615126990|
|Yeung AH,Cowan MJ,Horn B,Rosbe KW. Airway management in children with mucopolysaccharidosesArch Otolaryngol Head Neck SurgYear: 2009135737910.1001/archoto.2008.51519153310|
[Figure ID: Fig1]
Mechanisms that predispose to sleep disordered breathing in patients with mucopolysaccharidosis (MPS)
[Figure ID: Fig2]
Impaired compensation for sleep disordered breathing, leading to hypoventilation during sleep. Reproduced from Berger et al (Berger et al 2000), with permission from the American Physiology Society
[Figure ID: Fig3]
a Oropharyngeal image from a patient with mucopolysaccharidosis (MPS) II showing macroglossia and gingival hyperplasia; b normal lyaryngoscopic image; c-d laryngoscopic images from a patient with MPS II showing a thick laryngeal wall, tonsillar hyperplasia, and redundant arytenoid mucosa prolapse into laryngeal inlet; e-f nasal endoscopic images showing inflammation and abnormal mucous secretion in a patient with MPS VI; g normal bronchoscopic image (Canani et al 2003); h-j bronchoscopic image and CT scans from a patient with MPS IV showing tracheal deformity and narrowing; k-l typical frontal and lateral plain X-rays of the chest of a child with MPS II showing skeletal abnormalities and the presence of a tracheostomy and possibly infective changes in the lungs (hazy shadow in the right lower zone of the frontal image)
[Figure ID: Fig4]
Changes from baseline in forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) after initiation of enzyme replacement therapy (ERT). Results from a long-term extension study in patients with mucopolysaccharidosis VI (Harmatz et al 2010), reproduced with permission. n*: number of patients for whom data were available for that particular time point
Overview of types of mucopolysaccharidosis (MPS) and glycosaminoglycans that accumulate in each of these MPS types
|MPS||Dermatan sulfate (DS)||Heparan sulfate (HS)||Keratan sulfate (KS)||Chondroitin sulfate (CS)|
|I (H, HS, S)||Hurler, Hurler-Scheie, Scheie||+||+|
Key respiratory manifestations in the different mucopolysaccharidosis (MPS) types. Adapted from Muhlebach et al 2011, with permission from Elsevier Ltd
|MPS||Upper airway obstruction||Lower airway obstruction||Restrictive lung disease|
Manifestations of mucopolysaccharidosis (MPS) that may affect respiratory function and their prevalence in a study including 21 patients with MPS I, II, IV, VI, and VII. Adapted from Semenza et al (Semenza and Pyeritz 1988), with permission from Williams & Wilkins
|% of patients (N = 21)|
|Hypertrophy of tonsils/adenoids||67|
|Arterial hypoxemia awake||57|
|Arterial hypoxemia asleep||100|
|Thoracolumbar spine deformity|
|Cervical spine involvement|
|Cervical spine subluxation||68|
Previous Document: Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain m...
Next Document: Parental social support, coping strategies, resilience factors, stress, anxiety and depression level...